Results 11 to 20 of about 6,328 (205)

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

EJNMMI Radiopharmacy and Chemistry, 2023
Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Jean DaSilva, Clemens Decristoforo, Robert H. Mach, Guy Bormans, Giuseppe Carlucci, Mohammed Al-Qahtani, Adriano Duatti, Antony D. Gee, Wiktor Szymanski, Sietske Rubow, Jeroen Hendrikx, Xing Yang, Hongmei Jia, Junbo Zhang, Peter Caravan, Hua Yang, Jan Rijn Zeevaart, Miguel Avila Rodriquez, Ralph Santos Oliveira, Marcela Zubillaga, Tamer Sakr, Sarah Spreckelmeyer   +21 more
doaj   +2 more sources

Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023)

EJNMMI Radiopharmacy and Chemistry, 2023
The International Atomic Energy Agency (IAEA) held the 3rd International Symposium on Trends in Radiopharmaceuticals, (ISTR-2023) at IAEA Headquarters in Vienna, Austria, during the week of 16–21 April 2023.
Amirreza Jalilian, Clemens Decristoforo, Melissa Denecke, Philip H. Elsinga, Cornelia Hoehr, Aruna Korde, Suzanne E. Lapi, Peter J. H. Scott   +7 more
doaj   +1 more source

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

EJNMMI Radiopharmacy and Chemistry, 2022
Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Jun Toyohara, Mohammed Al-Qahtani, Ya-Yao Huang, Emiliano Cazzola, Sergio Todde, Shozo Furumoto, Renata Mikolajczak, Clemens Decristoforo, Nic Gillings, Min Yang, Raymond Reilly, Adriano Duatti, Antonia Denkova, Ralf Schirrmacher, Giuseppe Carlucci, Yann Seimbille, Zhaofei Liu, Beverley Ellis, Bart T. Cornelissen, Klaus Kopka, Emerson Bernardes   +20 more
doaj   +1 more source

Simultaneous Visualization of ¹⁶¹Tb- and ¹⁷⁷Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging

Pharmaceutics, 2021
The decay of terbium-161 results in the emission of β¯-particles as well as conversion and Auger electrons, which makes terbium-161 interesting for therapeutic purposes.
Francesca Borgna, Patrick Barritt, Pascal V. Grundler, Zeynep Talip, Susan Cohrs, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli, Nicholas P. van der Meulen, Cristina Müller   +9 more
doaj   +1 more source

A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides

EJNMMI Research, 2023
Purpose The angiotensin converting enzyme-2 (ACE2)—entry receptor of SARS-CoV-2—and its homologue, the angiotensin-converting enzyme (ACE), play a pivotal role in maintaining cardiovascular homeostasis.
Darja Beyer, Christian Vaccarin, Xavier Deupi, Ana Katrina Mapanao, Susan Cohrs, Fan Sozzi-Guo, Pascal V. Grundler, Nicholas P. van der Meulen, Jinling Wang, Matthias Tanriver, Jeffrey W. Bode, Roger Schibli, Cristina Müller   +12 more
doaj   +1 more source

Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK

EJNMMI Radiopharmacy and Chemistry, 2023
Background Peptidic radiotracers are preferentially excreted through the kidneys, which often results in high persistent renal retention of radioactivity, limiting or even preventing therapeutic clinical translation of these radiotracers.
Belinda Trachsel, Giulia Valpreda, Alexandra Lutz, Roger Schibli, Linjing Mu, Martin Béhé   +5 more
doaj   +1 more source

Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging

EJNMMI Radiopharmacy and Chemistry, 2021
Background Terbium-155 [T1/2 = 5.32 d, Eγ = 87 keV (32%) 105 keV (25%)] is an interesting radionuclide suitable for single photon emission computed tomography (SPECT) imaging with potential application in the diagnosis of oncological disease.
C. Favaretto, Z. Talip, F. Borgna, P. V. Grundler, G. Dellepiane, A. Sommerhalder, H. Zhang, R. Schibli, S. Braccini, C. Müller, N. P. van der Meulen   +10 more
doaj   +1 more source

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +1 more source

Special Issue “Targets, Tracers and Translation Novel Radiopharmaceuticals Boost Nuclear Medicine”

Pharmaceuticals, 2019
This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences [...]
Gerald Reischl
doaj   +1 more source

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source